Vetter receives AEO-F certificate from the European Union for global movement of goods.
On Dec. 1, 2015 Vetter Pharmaceuticals, a Germany-based contract development and manufacturing organization (CDMO), announced the company had received an Authorized Economic Operator Full (AEO-F) certificate for global movement of goods from the European Union.
According to the European Commission, to qualify for AEO-F certification, a company must demonstrate a good record of compliance with customs requirements, satisfactory system of managing commercial and transport, records which allow appropriate customs controls, proven financial solvency, and appropriate security and safety standards.
The AEO-F is currently accepted by the United States, Japan, European Union Member states, Switzerland, Norway, and China. Ecuador and El Salvador are expected to launch AEO programs by the end of 2015. According to the company, this certification will aid in facilitating the import of drugs, allowing it to transport pharmaceuticals more quickly, and at a lower cost.
The World Custom’s Organization (WCO) says there are currently a total of 12,367 AEO companies in the United States and Canada alone. Outside the North American market, the organization says there are a total of 450 AEO companies. By expanding the AEO programs, the WCO hopes to establish a uniform customs and security standard in the international movement of goods, with the Standards to Secure and Facilitate Global Trade (SAFE) program.
Vetter Pharmaceuticals has facilities in Germany and the United States. The company recently began operating a branch in Singapore, and Tokyo. The company focuses on fill and finish of aseptically prefilled syringe systems, cartridges, and vials; it also has services for the commercial filling and packaging of parenteral drugs.
Source: Vetter Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.